| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Outline of Final Research Achievements |
In a retrospective cohort study of 2,292 hemodialysis patients, treatment with lanthanum was independently associated with a significant survival benefit in hemodialysis patients with inadequately controlled hyperphosphatemia. We found no significant associations of better glycemic control or use of inhibitors of renin-angiotensin system with improved survival.
We also performed a prospective cohort study: a total of 654 hemodialysis patients were recruited and were prospectively followed for 3 years. Baseline median FGF23 levels and mean soluble Klotho levels were 1,878 pg/ml and 377 pg/ml, respectively. We will evaluate associations of FGF23 levels, soluble Klotho levels, and other patient characteristics with mortality and cardiovascular events.
|
